178258-76-9

Upstream product

• 150323-36-7 dihydro-5(S)-<<4-<(1,1-dimethylethoxy)carbonyl>-2(S)-(N-tert-butylcarbamoyl)piperazinyl>methyl>-3(R)-(phenylmethyl)-3(2H)-furanone 

Downstream Products

• 501676-24-0 (S)-1-((2S,4R)-4-Benzyl-5-oxo-tetrahydro-furan-2-ylmethyl)-4-(1,1-dimethyl-prop-2-ynyl)-piperazine-2-carboxylic acid tert-butylamide 
• 501676-27-3 1-[2-(tert-butyl-dimethyl-silanyloxy)-4-(2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-(7-iodo-furo[3,2-c]pyridin-2-yl)-1-methyl-ethyl]-piperazine-2-carboxylic acid tert-butylamide 
• 501676-26-2 2-benzyl-5-{2-tert-butylcarbamoyl-4-[1-(7-iodo-furo[3,2-c]pyridin-2-yl)-1-methyl-ethyl]-piperazin-1-yl}-4-(tert-butyl-dimethyl-silanyloxy)-pentanoic acid 
• 501676-25-1 1-(4-benzyl-5-oxo-tetrahydro-furan-2-ylmethyl)-4-[1-(7-iodo-furo[3,2-c]pyridin-2-yl)-1-methyl-ethyl]-piperazine-2-carboxylic acid tert-butylamide 

Relevant academic research and scientific papers

Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains

Indinavir analogues with blocked metabolism sites show highly improved pharmacokinetic profiles in animals. The cis-aminochromanol substituted analogues exhibited excellent potency against both the wild-type (NL4-3) virus and protease inhibitor-resistant HIV strains.